D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
DNLI holding history
Denali Therapeutics Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
DNLI overviewAll 13F holders of DNLIFull Q2 2026 holdings
- Shares (Q2 2025)
- 0
- Sold out in Q2 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 11
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2025 | 0 | $0 | 0.0% | −78,218−100.0% | Sold out | Holders |
| Q1 2025 | 78,218 | $1.06M | <0.1% | +78,218 | New | Holders |
| Q3 2024 | 0 | $0 | 0.0% | −29,721−100.0% | Sold out | Holders |
| Q2 2024 | 29,721 | $690.1K | <0.1% | −86,544−74.4% | Reduced | Holders |
| Q1 2024 | 116,265 | $2.39M | <0.1% | +116,265 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −44,336−100.0% | Sold out | Holders |
| Q1 2023 | 44,336 | $1.02M | <0.1% | −90,091−67.0% | Reduced | Holders |
| Q4 2022 | 134,427 | $3.74M | <0.1% | +134,427 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −86,113−100.0% | Sold out | Holders |
| Q2 2022 | 86,113 | $2.53M | <0.1% | +79,865+1,278.2% | Added | Holders |
| Q1 2022 | 6,248 | $201.0K | <0.1% | −988−13.7% | Reduced | Holders |
| Q4 2021 | 7,236 | $323.0K | <0.1% | −38,177−84.1% | Reduced | Holders |
| Q3 2021 | 45,413 | $2.29M | <0.1% | −38,172−45.7% | Reduced | Holders |
| Q2 2021 | 83,585 | $6.56M | <0.1% | −122,577−59.5% | Reduced | Holders |
| Q1 2021 | 206,162 | $11.8M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.